Exubrion Therapeutics® Appoints Jennifer Kirk to Board of Directors; Names Her CEO

ALPHARETTA, Ga., March 18, 2025 /PRNewswire/ -- Exubrion Therapeutics, the pioneering company behind Synovetin OA^®, an innovative injectable treatment that provides relief for dogs suffering from chronic osteoarthritis, announced today that Jennifer Kirk has been appointed to the company's Board of Directors and will assume the role of Chief Executive Officer effective May 3, 2025. Synovetin OA utilizes proprietary radiotherapeutic technology to deliver targeted, localized relief, helping dogs regain mobility and live pain-free for up to one year after a single treatment.

Kirk brings more than 28 years of leadership and business transformation experience, including a successful tenure at Medtronic, one of the world's leading medical technology companies. While at Medtronic, she held key executive leadership roles focusing on finance and operational growth. Her experience navigating complex, high-growth organizations in medtech and other industries uniquely positions her to lead Exubrion Therapeutics.

"We are thrilled to welcome Jennifer to the Exubrion Therapeutics leadership team," said Laurie McRay, Executive Chair and interim CEO. "Her energy, servant leadership, and extensive business experience make her the ideal person to guide us into our next phase of growth. Her proven ability to lead organizations and create value will be instrumental as we continue advancing our mission. We are fortunate to have her at the helm."

Throughout her career, Kirk has helped companies transform by fostering a culture of innovation; building high-performing teams; unlocking new growth opportunities; and finding ways to grow revenue and expand margins. She has also led teams that captured over $3.5 billion in savings and value by optimizing operations, streamlining efficiencies and driving strategic investments. Kirk holds an MBA plus additional certifications from Carnegie Mellon and Harvard Business School.

"I am honored and excited to join Exubrion Therapeutics as CEO," said Kirk. "Synovetin OA is a differentiated technology that has already uniquely transformed the treatment of canine osteoarthritis, delivering real, lasting relief for pets and their families. I'm eager to lead Exubrion Therapeutics into this next phase of growth, not only expanding our reach in the canine market but also unlocking the potential for Synovetin OA to help equine patients and, ultimately, all pets in need of effective osteoarthritis treatment. The opportunity to extend this breakthrough therapy into new areas both domestically and internationally is incredibly exciting, and I look forward to working with the team to make it a reality."

About Exubrion Therapeutics, Inc.

Exubrion Therapeutics is the developer of Synovetin OA, a breakthrough injectable treatment that provides long-lasting relief for dogs suffering from chronic osteoarthritis. Utilizing proprietary radiotherapeutic technology, Synovetin OA offers targeted, localized therapy to reduce joint inflammation and pain, often providing up to a full year of improved mobility and quality of life with a single treatment. For more information, visit https://activedognow.com/about-exubrion/.   

Studied in canine elbows, Synovetin OA is given by authorized veterinarians. Temporary discomfort in treated joints may occur. Talk to a treating veterinarian near you for more information including what to expect following treatment and visit www.activedognow.com.

Media Contact:
Eric Schreiber, Chief Commercial Officer
(610) 368-0815
[email protected] 

SOURCE Exubrion Therapeutics